Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2016

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)

L. Payen-Gay

Résumé

In addition to spliceosome gene mutations, oncogene expression and drug resistance in AML might influence exon expression. We performed exon-array analysis and exon-specific PCR (ESPCR) to identify specific landscapes of exon expression that are associated with DEK and WT1 oncogene expression and the resistance of AML cells to AraC, doxorubicin or azacitidine. Data were obtained for these five conditions through exon-array analysis of 17 cell lines and 24 patient samples and were extended through qESPCR of samples from 152 additional AML cases. More than 70% of AEUs identified by exon-array were technically validated through ESPCR. In vitro, 1,130 to 5,868 exon events distinguished the 5 conditions from their respective controls while in vivo 6,560 and 9,378 events distinguished chemosensitive and chemoresistant AML, respectively, from normal bone marrow. Whatever the cause of this effect, 30 to 80% of mis-spliced mRNAs involved genes unmodified at the whole transcriptional level. These AEUs unmasked new functional pathways that are distinct from those generated by transcriptional deregulation. These results also identified new putative pathways that could help increase the understanding of the effects mediated by DEK or WT1, which may allow the targeting of these pathways to prevent resistance of AML cells to chemotherapeutic agents
Fichier principal
Vignette du fichier
3898-110907-2-PB.pdf (3.25 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-01812676 , version 1 (10-04-2024)

Identifiants

Citer

A.M. Mohamed, M. Balsat, M. Thenoz, C. Koering, L. Payen-Gay, et al.. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget, 2016, 7, pp.2889-2909. ⟨10.18632/oncotarget.3898⟩. ⟨hal-01812676⟩
56 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More